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The A-kinase-anchoring protein AKAP79 co-ordinates the
location of cAMP-dependent protein kinase, phosphatase 2B
(PP2B}calcineurin) and protein kinase C (PKC) at postsynaptic
sites in neurons. In this report we focus on the mechanism of
interaction between AKAP79 and PKC. We show that neither
lipid activators nor kinase activation are required for association
with AKAP79. The anchoring protein binds and inhibits the
conserved catalytic core of PKCbII. AKAP79 also associates
with conventional, novel and atypical isoforms of PKC in itro
and in io, and immuno¯uorescence staining of rat hippocampal
neurons demonstrates that the murine anchoring-protein homo-
logue AKAP150 is co-distributed with PKCa}b, PKCe or PKCi.
Binding of the AKAP79(31±52) peptide, which inhibits kinase
activity, exposes the pseudosubstrate domain of PKCbII,
INTRODUCTION
Speci®c phosphorylation of intracellular substrates is important
for the control of many aspects of cellular function [1]. Protein
phosphorylation is a tightly regulated process involving the
concerted action of protein kinases and phosphatases. Recently,
targeting of these signalling enzymes to precise subcellular
locations has emerged as a mechanism for tight control of
phosphorylation events within a de®ned microenvironment [2,3].
Compartmentalization of protein kinases and phosphatases may
also increase the speed and ®delity of speci®c substrate phos-
phorylation and dephosphorylation in response to particular
second-messenger signals. This is achieved, in part, through
interactions with anchoring and targeting proteins [4]. A growing
number of these proteins has now been identi®ed, which bind
protein kinases and phosphatases speci®cally and frequently
regulate their location and activity [3,5]. For example, A-kinase-
anchoring proteins (AKAPs) bind to the regulatory subunit
(RII) of the cAMP-dependent protein kinase (PKA) and direct
the kinase to discrete subcellular structures [6,7].
The neuronal anchoring protein, AKAP79, is enriched in
postsynaptic fractions, and immunostaining in hippocampal
neurons reveals a concentration at the periphery of the cell body
and in neurite extensions [8±10]. AKAP79 targeting has recently
been shown to be mediated through three basic-rich regions that
bind acidic phospholipids and which appear to be regulated by
phosphorylationandcalmodulinbinding[11].WhereasAKAP79
was originally cloned as an RII-binding protein, it has also been
shown to associate with protein phosphatase 2B calcineurin and
protein kinase C (PKC) [10,12]. Thus AKAP79 directs three
signalling enzymes to postsynaptic sites and has been proposed
to function as a signalling scaﬀold co-ordinating the phos-
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allowing endoproteinase Arg-C proteolysis in the absence of
kinase activators. Reciprocal experiments have identi®ed two
arginine residues at positions 39 and 40 that are essential for
AKAP79(31±52) peptide inhibition of PKCbII. Likewise, the
same mutations in the full-length anchoring protein reduced
inhibition of PKCbII. Thus AKAP79 associates with multiple
PKC isoforms through a mechanism involving protein±protein
interactions at the catalytic core where binding of the anchoring
protein inhibits kinase activity through displacement of the
pseudosubstrate.
Key words: anchoring protein, postsynaptic density, signal
transduction, subcellular localization.
phorylation state of synaptic proteins [13]. However, there are
still questions surrounding mechanisms of interaction and regu-
lation of this signalling complex. Each enzyme associated with
the anchoring protein is maintained in an inactive state: the
catalytic (C) subunit of PKA through interactions with anchored
RII, whereas calcineurin and PKC bind through direct inter-
actions with the anchoring protein [10,12]. The catalytic subunit
of PKA is released as freely active enzyme following cAMP
bindingtoRII,whereastheregulatorymechanismforcalcineurin
is unknown. We have shown previously that Ca#+±calmodulin
antagonizestheinteractionbetweenAKAP79andPKC,releasing
the inhibited kinase from its association with the anchoring
protein [14]. However, the precise mechanism for the interaction
of AKAP79 and PKC is not fully understood.
In this study we have focused on the association of PKC with
the anchoring protein and have extended our understanding of
the mechanism of PKC±AKAP79 interaction in three ways.
First, PKC binds to the anchoring protein in a manner that does
not require lipid cofactors or activation of the kinase. Secondly,
the catalytic core of the kinase provides a principal site of contact
with AKAP79. Finally, a pair of arginine residues at positions 39
and 40 on AKAP79 participate in binding and inhibition of PKC
in a mechanism involving the pseudosubstrate.
EXPERIMENTAL
Bacterial expression and puriﬁcation of recombinant AKAP79
proteins
AKAP79 was expressed as an N-terminal His-tagged fusion
protein in pET16b (Novagen) in the BL21}DE3 strain of
Escherichia coli and puri®ed using Ni-aﬃnity chromatography
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(Pharmacia). For construction of the AKAP79 R39,40A mutant,
expression vectors encoding the cDNA sequence of AKAP79
with mutation of Arg-39 and Arg-40 to Ala were made by quick-
change site-directed mutagenesis (Stratagene) using wild-type
AKAP79 in pET16b as template. Synthetic oligonucleotide
primers were designed to introduce four nucleotide base changes
(shown here in bold): the nucleotide sequences of the sense and
antisense primers were GCATCCATGCTTTGCTTCAAGGC-
AGCAAAGAAAGCAGCCAAAGCACandGTGCTTTGGC-
TGCTTTCTTTGCTGCCTTGAAGCAAAGCATGGATGC.
The PCR product was digested with DpnI and transformed into
DH5a-competent cells. The sequence was veri®ed by DNA
sequencing.
Expression of PKC isoforms and mutants
Sf21 insect cells were infected with high-titre (1¬10) plaque-
forming units[ml−") baculovirus encoding wild-type PKC iso-
forms(a, bII, d, e, f and h) or mutants of PKC bII (GST±PKCbII
kinase domain [15], K371R, T500V and D248R}D254R; where
GST is glutathione S-transferase), as described in [16]. The cells
were harvested after 3 days at 27 °C, lysed by homogenization in
buﬀer containing 50 mM Hepes (pH 7.4), 0.2% Triton X-100,
1 mM EDTA, 1 mM EGTA, 1 mM dithiothreitol (DTT), 85 lM
leupeptin, 2 mM benzamidine and 0.2 mM PMSF, and centri-
fuged at 100000 g for 20 min at 4 °C. Experiments were
performed with the supernatant (detergent-soluble) diluted 2-
fold in glycerol and stored at ®20 °C.
Immunoprecipitation of AKAP79
AKAP79 (2 lg) was incubated with detergent-soluble extracts
(100 lg) of Sf21 insect cells expressing PKC in hypotonic buﬀer
[10 mM Hepes, pH 7.4, 1.5 mM MgCl#, 10 mM KCl, Nonidet P-
40 (0.2% w}v), 1 mM DTT, 2 mM CaCl#,2 0lg}ml phospha-
tidylserine (PS), 0.1% BSA, 1 mM benzamidine, 2 lg}ml leu-
peptin, 2 lg}ml pepstatin and 100 mM 4-(2-aminoethyl)-
benzenesulphonyl ¯uoride hydrochloride] for 1 h at 4 °C.
AKAP79 was immunoprecipitated using an AKAP79-speci®c
antibody (918I from Icos, Seattle, WA, U.S.A.) followed by
detection of various PKC isoforms by Western blotting as
described in [14]. For immunoprecipitation in the presence of
diﬀerent lipids, PS (20 lg}ml) was substituted with 140 lM PS,
140 lM phosphatidic acid (PA), 140 lMP S }4.0 lM diacyl-
glycerol (DG; all from Avanti), or 100 nM phorbol ester (PMA;
Sigma). Lipid solutions were prepared from chloroform stock
solutions by drying the solutions with nitrogen and resuspending
the lipid in 20 mM Hepes (pH 7.4) and sonicating for 30 s. For
immunoprecipitation of AKAP79 with PKCbII mutants,
Western-blotanalysiswasperformedwithamonoclonalantibody
to PKCa}b (Transduction Laboratories). For immunopreci-
pitation of AKAP79 with diﬀerent PKC isoforms, AKAP79 was
incubated with Sf21 cells expressing PKCa, PKCbII, PKCd,
PKCe, PKCh and PKCf. Western-blot analysis was performed
with isoform-speci®c antibodies (a, d, e, h and i from Trans-
duction Laboratories; f and bII from Santa Cruz Biotech-
nology). AKAP79 (10 lg) was also immunoprecipitated with
Sf21 cells expressing the GST-tagged catalytic core of PKC
(100 lg).
PKC activity assay
PKCbII was assayed as described in [14]. PKCbII catalytic-
domain activity was assayed in the presence of 2 mM EGTA and
0.1% (w}v) Triton X-100. Dose±response curves were generated
over an inhibitor concentration range of 0.1±10 lM for AK-
AP79(31±52) and AKAP79(31±52) (R39,40A) peptides and
0.1±5 lM for AKAP79 wild-type and full-length AKAP79
(R39,40A) mutant proteins.
PKCbII proteolysis
Limited trypsin digestion of PKCbII was conducted as described
in [14]. Proteolytic products were then assayed for PKC activity
in the presence of PKC activators: 300 lM CaCl#}0.1% (w}v)
Triton X-100 micelles containing 20 mol% PS and 5 mol%
dioleoylglycerol (Avanti). Limited endoproteinase Arg-C di-
gestion of PKCbII was performed as described in [17] in a total
volume of 80 ll (containing 20 mM Hepes, pH 7.5, 2 mM DTT,
300 lM CaCl#, 140 lM PS and 3.8 lM DG) in the presence of 8
units}ml endoproteinase Arg-C. For experiments with peptides,
PKCbII was pre-incubated with 100 lM AKAP79(31±52) or
100 lM AKAP79(31±52) (R39,40A). The reaction was stopped
by the addition of 25 ll of sample-preparation buﬀer, and
proteolytic fragments were separated by SDS}PAGE (9% gels)
and transferred on to nitrocellulose. Immunoblots were probed
with antibodies to PKCbII (Santa Cruz Biotechnology).
PKC overlay
PKC binding was assayed by modi®cation of the overlay assay
described by Hyatt et al. [18]. Proteins were separated by
SDS}PAGE and transferred on to nitrocellulose. Filters were
washed three times with Tris-buﬀered saline (TBS; 10 mM Tris,
pH 7.6, 140 mM NaCl), blocked in Blotto (TBS with 5% non-fat
dry milk and 0.1% BSA) for 30 min, and washed three times
with TBS. Filters were then incubated with PKC (titrated
amounts of PKC isoforms according to expression levels of the
Sf21 cell extracts) in assay buﬀer [TBS containing 1% BSA,
1.2 mM CaCl#, 1 mM EGTA, 20 lg}ml PS, 1 mM benzamidine,
2 lg}ml leupeptin, 2 lg}ml pepstatin and 100 mM 4-(2-
aminoethyl)benzenesulphonyl ¯uoride hydrochloride] for 1 h.
Filters were again washed three times with TBS, and incubated
with isoform-speci®c antibodies. For overlays conducted in the
presence of peptides, PKC was pre-incubated in assay buﬀer with
2.0 lM peptide for 1 h at 4 °C.
Co-puriﬁcation of AKAP150 and PKC using cAMP–agarose
Rat brain extracts were prepared by grinding frozen Sprague±
Dawley unstripped rat brains (Pelfreze) in liquid nitrogen,
followed by Dounce homogenization in lysis buﬀer [20 mM
Hepes, pH 7.4, 20 mM NaCl, 5 mM EDTA, 5 mM EGTA,
0.5% Triton X-100, 1 mM DTT, 1 mM benzamidine, 2 lg}ml
leupeptin, 2 lg}ml pepstatin and 100 mM 4-(2-aminoethyl)-
benzenesulphonyl ¯uoride hydrochloride] and centrifugation at
15000 g for 30 min at 4 °C. Experiments were performed with
pre-incubation of supernatant in the absence and presence of
50 mM cAMP (Sigma). Extracts were incubated with cAMP±
agarose for 18 h at 4 °C. Following incubation, the resin was
washed twice with hypotonic buﬀer [10 mM Hepes, pH 7.4,
1.5 mM MgCl#, 10 mM KCl, 0.1% Nonidet P-40, 1 mM DTT,
1 mM benzamidine, 2 lg}ml leupeptin, 2 lg}ml pepstatin, and
100 mM 4-(2-aminoethyl)-benzenesulphonyl ¯uoride hydrochlo-
ride] containing 0.5 M NaCl, and four times with hypotonic
buﬀer without NaCl. Proteins were eluted from the resin by
incubation with 75 mM cAMP for 1 h at room temperature.
Eluted proteins were precipitated with 6% trichloroacetic acid
and resuspended in SDS-sample preparation buﬀer. Proteins
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were separated by SDS}PAGE on a 4±15% gradient gel and
transferred on to nitrocellulose. Filters were analysed by Western
blotting with PKC-isoform-speci®c antibodies and an antibody
to AKAP150 (4361J).
Immunocytochemistry
Cultured neonatal hippocampal neurons were ®xed and per-
meabilized as described in [14]. Cells were blocked in PBS
containing 0.2% BSA for 1 h and then incubated with mix-
tures containing aﬃnity puri®ed rabbit anti-AKAP150 antibody
4361J and mouse anti-PKCa, anti-PKCe or anti-PKCi or aﬃnity
puri®ed goat anti-RII. Coverslips were washed three times with
PBS containing 0.2% BSA and incubated with a mixture of
FITC-conjugated anti-rabbit (1:200), Texas Red-conjugated
anti-mouse (1:200) and Cy5-conjugated anti-goat (1:500)
secondary antibodies (all from Jackson) in PBS containing
0.2% BSA. The coverslips were then washed three times in PBS
containing 0.2% BSA, washed in Nanopure water and mounted
with Prolong (Molecular Probes). Cells were analysed with a
Bio-Rad confocal microscope [19].
RESULTS
Interaction of AKAP79 and PKCbII does not require lipid
activators
WehaveshownpreviouslythatPKCbIIassociateswithAKAP79
in a Ca#+-independent manner and in the presence of PS [10,14].
However, the precise activation state of the kinase when bound
to the anchoring protein is not known. Activation of PKCbII
requires DG, PS and Ca#+ [20]. In addition, we have shown
recentlythatsub-membranetargetingofAKAP79involvesacidic
phospholipids that bind to distinct regions on the anchoring
protein, including PtdIns(4,5)P# and PS [11]. In order to assess
whether lipid bridging mediated AKAP79±PKC interactions, the
anchoring protein was incubated with PKCbII and co-pre-
cipitation experiments were performed in the presence or absence
of lipid and activators (Figure 1). Immunoblot analysis demon-
strates that PKCbII co-immunoprecipitated with AKAP79 in-
dependently of the presence of PS or PA (Figure 1A). Control
experiments with pre-immune sera did not detect the enzyme
Figure 1 AKAP79 binding to PKCbII does not require lipid activators
AKAP79 (2 lg) and soluble Sf21 cell lysate (100 lg) expressing PKCbII were incubated in
the presence of 140 lM PS, 140 lM PA or no lipid (A), and 140 lM PS/4 lM DG or 0.1 lM
PMA (B) for 1 h at 4 °C. Proteins were immunoprecipitated with a polyclonal antibody to
AKAP79 918I (I. P.) or preimmune serum as described in the Experimental section. Precipitated
proteins were immunoblotted and detected with a monoclonal antibody to PKCa/b. The
migration of PKCbII is indicated. Shown is a representative of at least three separate
experiments. Molecular-mass markers are indicated in kDa.
Figure 2 AKAP79 binds PKCbII activation-site mutants
AKAP79 (2 lg) and soluble Sf21 cell lysate (100 lg) expressing PKCbII mutants K371R,
D248R/D254R and T500V were incubated for 1 h at 4 °C. Proteins were immunoprecipitated
with a polyclonal antibody to AKAP79 918I (I. P.) or preimmune sera as described in the
Experimental section. Precipitated proteins were immunoblotted and probed with a monoclonal
antibody to PKCa/b. Shown is a representative of at least three separate experiments.
Molecular-mass markers are indicated in kDa.
(Figure 1A). Signi®cantly, PKCbII co-precipitated when lipid
was not present (Figure 1A). The kinase also co-precipitated
with AKAP79 in the presence of both PS}DG and PMA (Figure
1B) as well as with PA}DG (results not shown). These results
establish that lipid is not required for interaction of PKC and
AKAP79 and suggest that the activation state of PKC is not
signi®cant for association with the anchoring protein.
PKCbII does not need to be in an active conformation to bind
AKAP79
In order to investigate further the mechanism of PKCbII binding
to AKAP79, co-precipitation experiments were performed with
mutants of PKCbII. Mutation of the invariant Lys residue in the
ATP-binding site of Ser}Thr kinase catalytic domains renders
the kinase inactive [21]. Mutation of this essential Lys to Arg in
PKCbII (K371R) did not abolish binding to AKAP79 (Figure
2). Other studies have shown that phosphorylation at the
activation loop is required for cofactor generation of the mature
activatable conformation of PKCbII [22,23]. However, mutation
of the activation-loop phosphorylation site, Thr-500 to Val
(T500V)inPKCbII,didnotabolishtheinteractionwithAKAP79
(Figure 2). We also investigated the eﬀect of mutations in the
regulatory C2 domain (the Ca#+-dependent PS-binding domain)
of PKCbII on AKAP79 binding. Replacement of two acidic
residues with two basic charges in the Ca#+-binding site of
PKCbII (D248R}D254R) decreases Ca#+ binding as well as
anionic-lipid aﬃnity for PKCbII [16]. This C2-domain mutant
also co-precipitated with AKAP79 (Figure 2), consistent with
previous results showing that Ca#+ is not required for PKCbII
binding to the anchoring protein [14]. Collectively, the data
presented in Figures 1 and 2 suggest that PKCbII binds to
AKAP79 regardless of the presence of lipid activators of PKC
and that the active conformation of the enzyme is not important
for the interaction.
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Figure 3 AKAP79 binds PKCbII catalytic core
PKC (30 nmol) was digested with trypsin (300 ng/ml) to generate a constitutively active enzyme, as described in the Experimental section. (A) Dose-response curves of activator-independent PKCbII
activity in the presence of increasing concentrations of AKAP79(31±52) peptide assayed in the presence (E) and absence (D) of PKC activators (PS/DG and Ca2+). Values shown are
mean³S.E.M. (n¯3). (B) Dose±response curve of the activity of a recombinant PKCbII catalytic-domain fragment assayed in the presence of increasing concentrations of AKAP79(31±52) peptide
(E) and AKAP79 protein (U). Values shown are mean³S.E.M. (n¯3). (C) AKAP79 (10 lg) was incubated with soluble Sf21 cell lysate (100 lg protein) expressing GST±PKCbII catalytic
domain for 1 h at 4 °C. (D) Proteins were immunoprecipitated with a polyclonal antibody to AKAP79 918I (I. P.) or preimmune serum.
AKAP79 interacts with PKCbII catalytic core
Further mapping studies were conducted to determine which
regions of the kinase were required for association with AKAP79
[10].TrypsindigestionofPKCbIIremovestheregulatorydomain
of the kinase to generate a constitutively active catalytic core
[24], as evidenced by similar activities in the presence or absence
of PKC activators (Figure 3A). This trypsin-generated catalytic
fragment of PKCbII was inhibited to the same extent as the
intact enzyme by a peptide derived from AKAP79, residues
31±52 [10] (Figure 3A). This peptide has previously been shown
to act as a competitive inhibitor of kinase activity and block the
AKAP79±PKC interaction in itro [10]. Likewise, the enzymic
activity of a GST±PKCbII catalytic-domain fusion protein was
inhibited by both the AKAP79(31±52) peptide and the full-
length anchoring protein in a dose-dependent manner, with IC&! values of 0.9³0.3 (n¯4) and 2.7³0.2 lM( n¯3) respectively
(Figure 3B). To look more directly at AKAP79 binding to the
catalytic domain, we performed co-precipitation experiments
with Sf21 cell extracts expressing the GST±PKCbII catalytic-
domain fragment and incubated with recombinant AKAP79
(Figure 3C). In these experiments, a 5.6(³0.4)-fold increase
(n¯6) in activator-independent PKC activity over control was
measured in material immunoprecipitated with an antibody to
AKAP79 (Figure 3D). Complementary experiments demon-
strated that the GST±PKCbII catalytic domain co-immuno-
precipitated with AKAP79, but not with preimmune sera or
when AKAP79 was not added (results not shown). Taken
together, these results suggest that AKAP79 interacts with the
catalytic domain of PKCbII.
AKAP79 interacts with conventional, novel and atypical isoforms
of PKC
In light of our binding and inhibition studies, it is clear that
AKAP79 associates with sites in the catalytic core of PKCbII. As
all PKC isoforms exhibit a high degree of conservation in the
kinase catalytic core, we used two reciprocal approaches: PKC
overlay analysis and co-precipitation of AKAP79±PKC com-
plexes to determine which additional PKC isoforms bind the
anchoring protein in itro (Figure 4). Solid-phase overlay assays,
using diﬀerent isoforms of PKC as probes, demonstrate that
AKAP79 binds conventional isoforms, PKCa and bII, as well as
novel isoforms, PKCd and e, and atypical PKCf (Figure 4A). In
separate experiments, solution-phase interaction of AKAP79
with individual PKC isoforms was con®rmed by immunopre-
cipitation of the anchoring-protein±PKC complex from Sf21 cell
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Figure 4 AKAP79 binds multiple PKC isoforms in vitro
(A) PKC overlays. AKAP79 (2 lg) was separated by SDS/PAGE and transferred on to
nitrocellulose. Filters were probed with soluble Sf21 cell lysates expressing PKCa, PKCbII,
PKCd, PKCe and PKCf and overlay binding detected using isoform-speci®c antibodies as
described in the Experimental section. Each PKC isoform is denoted above each lane and the
migration position of AKAP79 is indicated. (B±G) Co-precipitation of AKAP79 and PKC
isoforms. AKAP79 (2 lg) was incubated with PKC isoforms, soluble Sf21 cell lysates (100 lg
of protein) expressing PKCa, PKCbII, PKCd, PKCe, PKCh or PKCf, for 1 h at 4 °C. Proteins
were immunoprecipitated with a polyclonal antibody to AKAP79 918I (I. P.) or preimmune
serum. Precipitated proteins were immunoblotted and probed with antibodies to the speci®c
PKC isoforms: (B) PKCa,( C) PKCbII, (D) PKCd,( E) PKCe,( F) PKCh or (G) PKCf as
described in the Experimental section. Each PKC isoform is denoted. Shown is a representative
of at least three separate experiments. Molecular-mass markers are indicated in kDa.
extracts expressing PKCa, PKCbII, PKCd, PKCe, PKCh or
PKCf (Figures 4B±4G respectively). Immunoblots probed with
the appropriate PKC antibody speci®cally detected co-precipi-
tation of each isoform with AKAP79 (Figures 4B±4G). Pre-
immune sera were used as a control to con®rm that individual
PKC isoforms did not non-speci®cally bind to IgG (Figures
4B±4G). In addition, AKAP79 does not bind the free catalytic
subunit of PKA [10], suggesting a speci®c interaction with PKC
isoforms.
While it is clear that AKAP79 binds all classes of PKC
isoforms in itro, it was important to determine which isoforms
interact with the anchoring protein inside cells. In order to
conduct these experiments, we took advantage of the fact that
AKAP79 also interacts with the PKA holoenzyme [8]. We used
aﬃnity puri®cation of the regulatory subunit of PKA on
cAMP±agarose to co-purify AKAP150 (the rat homologue of
human AKAP79) and PKC from rat brain extracts (Figure 5A).
Initial experiments con®rmed that AKAP150 was speci®cally
eluted from cAMP±agarose in buﬀers containing excess cAMP
(Figure 5B). Co-puri®cation of individual PKC isoforms from
Figure 5 Co-puriﬁcation of AKAP150, the rat homologue of AKAP79, with
PKC isoforms from rat brain extracts
(A) A schematic representation of cAMP±agarose co-puri®cation of RII, AKAP and PKC. Rat
brain extracts were incubated with cAMP±agarose and co-purifying proteins eluted with cAMP
and immunoblotted as described in the Experimental section. Eluant refers to speci®c elution
with cAMP. Control experiments were performed by pre-incubating extracts in the presence of
excess cAMP. Immunoblots were probed with antibodies to AKAP150 4361J (B), PKCa/b (C),
PKCbII (D), PKCd (E), PKCe (F), PKCf (G) and PKCi (H). The migration position of AKAP150
is indicated. Shown are representatives of at least three separate experiments. Molecular-mass
markers are indicated in kDa.
rat brain was detected using isoform-speci®c antibodies.
PKCa}b, PKCbII, PKCd, PKCe, PKCf and PKCi (Figures
5C±5H respectively) were eluted selectively from the resin with
excess cAMP. Control experiments con®rmed that the anchoring
protein complex was speci®cally interacting with the cAMP
ligand,as no AKAP150 or PKCwas recovered from extracts pre-
incubated with the aﬃnity resin in the presence of excess cAMP
(Figures 5C±5H). Importantly, these experiments show that the
rat homologue of AKAP79 interacts with various PKC isoforms
in the brain.
AKAP79 is a neuronal protein that is highly expressed in
certainbrainregionsandpresentinpostsynapticdensityfractions
[8,9]. It has been shown previously that AKAP150, the rat
homologue of AKAP79, is concentrated at the periphery of
neuronal cell bodies and in discrete dendritic regions of neurons
[9,10]. Therefore, we took an immunocytochemical approach to
examine the subcellular distribution of AKAP150, RII and
selected PKC isoforms in cultured rat hippocampal neurons. As
expected, AKAP150 is present at the periphery of the cell body
and exhibits a punctuate distribution in neurite extensions
(Figures 6A, 6D, 6G and 6J). The staining patterns of each PKC
isoform examined were distinct, but overlapped with the ancho-
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Figure 6 Subcellular distribution of AKAP150 and selected PKC isoforms in neurons
Neonatal rat hippocampal neurons were ®xed with 3.7% formaldehyde and permeabilized with 100% acetone at ®20 °C for 1 min. Cells were incubated with antibodies to AKAP150 (aﬃnity-puri®ed
rabbit 4361J) and PKCa/b, PKCe or PKCi (mouse monoclonal antibodies). Control experiments detected the regulatory subunit of PKA, RII (aﬃnity-puri®ed goat anti-RII antibodies). Protein staining
was detected with FITC-conjugated anti-rabbit (1:200), Texas Red-conjugated anti-mouse (1:200) and Cy5-conjugated anti-goat (1:500) secondary antibodies. Images were analysed by confocal
microscopy at ¬63 magni®cation, as described in the Experimental section. (A, D, G, J) AKAP150; (B) PKCa/b;( E) PKCe;( H) PKCi; and (K) RII. (C, F, I, L) Double-label immuno¯uorescent
composite images were analysed in the same focal plane.
ring protein (Figures 6C, 6F and 6I). The conventional isoforms
PKCa and PKCb were concentrated in the neuronal cell body
and excluded from the nucleus, with less staining in neuronal
extensions (Figure 6B). The non-conventional isoform PKCe
was largely in the cell body, but there was also de®ned staining
in dentrite extensions (Figure 6E). The atypical isoform PKCi
appeared to be concentrated in the cell body and was present to
a lesser extent in neuronal extensions with a more punctuate
distribution (Figure 6H). Composite images show that there is
some overlap in the staining pattern of PKC isoforms a}b, e or
i with AKAP150 (Figures 6C, 6F and 6I). Analysis of confocal
images suggests that each PKC isoform and AKAP150 occupy
the same focal plane, particularly in the cell body of each neuron
(Figures 6C, 6F and 6I). These observations are consistent with
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Figure 7 AKAP79(31–52) peptide exposes the pseudosubstrate domain of
PKCbII to Arg-C proteolysis
PKCbII was digested with endoproteinase Arg-C as described in the Experimental section.
Experiments were performed in the absence of PKC activators and (A) in the absence of
AKAP79 peptides, (B) in the presence of AKAP79(31±52) peptide, (C) in the presence
of AKAP79(31±52) (R39,40A) peptide. Shown is a time course of Arg-C digestion at 0, 15, 30
and 45 min. PKCbII was detected by immunoblot using an antibody to PKCbII. Shown is a
representative of at least three separate experiments.
the co-distribution of both proteins and support our data on the
isolation of PKC}AKAP complexes from rat brain. However,
there are clearly regions of distinct staining for each PKC
isoform. These ®ndings are analogous to the situation with type-
II PKA anchoring, where RII isconcentrated inthe cellbody and
present in neurite extensions, but is excluded from the nucleus
(Figures 6J±6L). Also, the composite image (Figure 6L) is
consistent with biochemical evidence that RII and AKAP150
associate in neurons [8,9,25]. Collectively, immunocytochemical
staining of AKAP150, RII and the PKC isoforms demonstrates
that a fraction of these proteins is co-distributed in neurons and
is consistent with the in itro and in io co-puri®cation experi-
ments described above.
Binding of AKAP79(31–52) peptide to PKCbII exposes the
pseudosubstrate sequence allowing Arg-C proteolysis in the
absence of PKCbII activators
InaneﬀorttounderstandthemechanismofAKAP79interaction
with the catalytic core of PKC more precisely, we used endo-
proteinase Arg-C digestion of PKCbII. Previous studies have
shown that limited proteolysis of PKCbII by endoproteinase
Arg-C, in the presence of PKC activators, cleaves the pseudo-
substrateregiontogeneratea78-kDaform[17].Thiscorresponds
to the cleavage of Arg-19 within the autoinhibitory pseudo-
substrate region of PKCbII. Mechanistic studies suggest that
upon activation the enzyme undergoes a conformational change
that releases the pseudosubstrate, allowing substrate access to
the active site [26]. Given that the AKAP79(31±52) peptide
inhibits PKCbII activity, we were interested in determining if this
peptide bound PKCbII with a similar mechanism to the pseudo-
substrate. As expected, PKCbII was not sensitive to Arg-C in
the absence of PKC activators (Figure 7A), but the 78-kDa
fragment was generated when the experiments were performed in
the presence of activators (results not shown). Interestingly,
incubation of PKCbII with the AKAP79(31±52) peptide pro-
motes the formation of a 78-kDa fragment in the absence of
activators, indicating exposure and cleavage of the pseudo-
substrate (Figure 7B). Thus it appears that the AKAP79(31±52)
peptide binds to PKCbII in a way that exposes Arg-19. On the
basis of these ®ndings we propose that the AKAP79 peptide
binds at or close to the substrate-binding groove in the catalytic
core of the kinase to displace the pseudosubstrate.
Molecular modelling of the catalytic core of PKC indicates
that Arg-19 is surrounded by a cluster of acidic residues when the
pseudosubstrate is bound to the substrate-binding site [27].
Interestingly, the AKAP79(31±52) peptide resembles the pseudo-
substrate, as it is rich in basic residues and inhibits PKC
activity, consistent with binding at this site [10]. In addition, this
peptide mimics activator-dependent digestion of PKCbII by
Arg-C,indicatingthatpeptidebindingresultsinaconformational
change, presumably by competing with the pseudosubstrate
(Figure 7B). To address the importance of basic residues in
AKAP79 binding to PKC, we replaced two Arg residues (Arg-39
and Arg-40) with Ala in the (31±52) peptide (see Figure 8A). The
AKAP79(31±52) (R39,40A) peptide did not result in signi®cant
digestion of PKCbII by Arg-C in the absence of activators
(Figure 7C). Thus, it appears that the arginine pair within the
AKAP79(31±52) peptide are essential for exposing the pseudo-
substrate to cleavage by endoproteinase Arg-C.
Arg-39 and Arg-40 are important for AKAP79 inhibition of PKCbII
To investigate further the role of Arg-39 and Arg-40 for binding
of PKC (Figure 8A), we tested the ability of the modi®ed (31±52)
(R39,40A) peptide to block PKCbII binding by overlay. The
(31±52) (R39,40A) peptide did not block PKCbII binding to
AKAP79 (Figure 8B, right panel), whereas the wild-type peptide
was able to block PKC binding (Figure 8B, left panel). In
addition, the AKAP79(31±52) (R39,40A) peptide was a poor
inhibitor of PKCbII activity (Figure 8C, E), whereas the wild-
type AKAP79(31±52) peptide was a potent inhibitor of kinase
activity (Figure 8C, D). To rule out the possibility that this
inhibition was due to PKC preferentially binding any basic pep-
tide, additional control experiments were performed with a
peptide of similar basic charge but of diﬀerent sequence from the
(31±52) peptide. This randomized peptide was unable to inhibit
the kinase (Figure 8C, *). In order to investigate the eﬀect of
Arg-39 and Arg-40 on PKC binding and inhibition in the context
of the full-length AKAP79 protein, we mutated both residues to
alanine. The AKAP79 (R39,40A) mutant protein shifted the
dose response of inhibition when compared with the wild-type
anchoring protein (Figure 8D). At an inhibitor concentration of
5 lM, PKCbII activity was reduced to 10% with the wild-type
anchoring protein but only to 50% with the AKAP79 (R39,40A)
mutant (Figure 8D). The partial eﬀects observed with the full-
length AKAP79 (R39,40A) mutant suggest that additional
determinants for interaction with PKCbII reside within the
anchoring protein. This idea was con®rmed by co-immuno-
precipitation of the AKAP79 (R39,40A) mutant with PKCbII
(Figure 8E). Collectively, these results demonstrate that basic
residues Arg-39 and Arg-40 within the AKAP79 PKC-binding
region are important for inhibition and binding in the (31±52)
peptide sequence and in¯uence inhibition of PKCbII activity in
the context of the full-length anchoring protein.
DISCUSSION
In this study we have extended our analysis of AKAP79±PKC
interaction in order to understand the mechanism of these
protein±protein interactions. There are now an increasing num-
ber of PKC-binding proteins believed to play a role in directing
the location of individual PKC isoforms to particular subcellular
locations (reviewed in [4,5]). These include: substrate-binding
proteins that interact with PKC prior to their phosphorylation
[28,29]; receptors for activated C-kinase (RACKs) proposed to
bind at site(s) distinct from the substrate-binding pocket of the
kinase [30,31]; PICK-1 (proteins that interact with C-kinase), a
protein cloned in two-hybrid screens that interacts with the C-
terminal tail of PKCa [32,33]; and GAP43, which binds PKCd in
neurons [34]. However, AKAP79 represents a distinct class of
PKC-targeting protein, as the anchoring protein inhibits kinase
activity as it binds to the catalytic core of the enzyme. In fact, all
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Figure 8 Arginines 39 and 40 in AKAP79 contribute to inhibition of PKCbII activity
(A) Amino acid sequences of the AKAP79(31±52) peptide and the modi®ed AKAP79(31±52) (R39,40A) peptide. (B) AKAP79 was blotted and PKCbII overlays performed in the presence of 2.0 lM
AKAP79(31±52) peptide (left panel) and 2.0 lM AKAP79(31±52) (R39,40A) (right panel). (C) Concentration response of PKCbII activity assayed in the presence of AKAP79(31±52)
(D), AKAP79(31±52) (R39,40A) (E) and control (*) peptides. Values shown are mean³S.E.M. (n¯3). In order to test the role of both arginine residues within the context of the full-length
protein or double mutant, AKAP79 (R39,40A) was constructed and puri®ed as described in the Experimental section. (D) Concentration±response curve of PKCbII activity assayed in the presence
of AKAP79 wild-type protein (D) and AKAP79 (R39,40A) mutant protein (E). Values shown are mean³S.E.M. (n¯3). (E) AKAP79 wild-type protein (2 lg) or AKAP79 (R39,40A) mutant protein
(2 lg) in the presence of soluble Sf21 cell lysate (100 lg) expressing PKCbII were incubated for 1 h at 4 °C. Proteins were immunoprecipitated with a polyclonal antibody to AKAP79 918I
(I. P.) or preimmune serum as described in the Experimental section. Precipitated proteins were immunoblotted and probed with a monoclonal antibody to PKCa/b. Shown is a representative
of at least three separate experiments. Molecular-mass markers are indicated in kDa.
of the PKC isoforms tested were able to bind AKAP79 in itro
and inside cells, in accordance with PKCs and AKAP79 being
bound to membranes, whereas RACKs and PICK-1 have been
reported to be isoform-selective [30,32]. Unlike the other PKC-
targeting proteins, AKAP79 localizes three signalling enzymes,
PKA, calcineurin and PKC, to postsynaptic membranes
[11,12,35]. Association with the anchoring protein forms a
signalling scaﬀold that optimally positions each enzyme just
below the postsynaptic membrane where it can respond in-
dividually to activation signals such as the in¯ux of calcium or
the generation of the second messengers, cAMP and DG [13].
Thus AKAP79 may represent a point of convergence for
Ca#+±calmodulin- and DG-signalling pathways that regulate
PKC-phosphorylation events at the postsynaptic membrane.
Another issue addressed in this study relates to the site of
AKAP79 interaction with the kinase. PKC is maintained in a
dormant state through intrasteric interactions between a
pseudosubstrate region in the regulatory domain and the sub-
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strate-binding cleft of the kinase catalytic core [27]. Since PKC is
inactive when bound to AKAP79, it seemed likely that the active
siteofthekinasewouldparticipateinprotein±proteininteractions
with the anchoring protein, particularly as the PKCbII catalytic
core binds and is inhibited by AKAP79. However, point muta-
tions in the ATP-binding site or the activation loop of PKC that
render the kinase inactive did not prevent AKAP79 binding.
These results suggest two possibilities: an active kinase con-
formation is not required for interaction with AKAP79, and}or
that there are multiple sites of contact on the kinase core for
association with the anchoring protein. In support of the latter
hypothesis, we have evidence that the AKAP79 (R39,40A)
mutant still binds the PKC catalytic core but inhibits the kinase
to a lesser extent (M. C. Faux and J. D. Scott, unpublished
work). One site of contact may include the substrate-binding
groove on the lower lobe of the kinase catalytic core, as we have
shown that themechanism ofAKAP79(31±52) peptide inhibition
demonstrates strong elements of competitive inhibition [10].
Moreover, proteolysis experiments imply that binding of the
anchoring protein alters the conformation of PKC in a way that
exposes the auto-inhibitory pseudosubstrate. On the basis of
these data it is reasonable to postulate that PKC adopts an open
conformation [27] when associated with AKAP79. Interestingly,
our ®ndings also indicate that there is no apparent involvement
of the PKC activator DG or phospholipid cofactors for inter-
action with the anchoring protein. This indicates further that
the kinase is not required to undergo full activation in order
toassociatewiththeanchoringprotein,andplacesmoreemphasis
on the role of protein±protein interactions for PKC±AKAP79
interaction. However, lipids do bind other sites on AKAP79, as
recent targeting studies have identi®ed regions of basic amino
acids on the anchoring protein that facilitate association with the
plasma membrane through interaction with acidic phospholipids
[11].
The molecular basis for pseudosubstrate inhibition was de-
veloped from the concept that regulatory sequences mimicking
substrate-recognition motifs are able to compete for binding to
the active site of a kinase [36]. Basic residues represent key
determinants in PKC±pseudosubstrate interactions, and mol-
ecular modelling of the PKC catalytic core reveals a cluster of
acidic residues within the substrate-binding groove that may
form a reciprocal binding surface [27]. As with the pseudo-
substrate, the principal PKC-binding site on AKAP79 (residues
31±52) is highly basic. Another parallel with pseudosubstrate-
likeinteractionsisprovidedbyevidencethattheAKAP79(31±52)
peptide inhibits PKC activity and results in exposure of Arg-19
in the pseudosubstrate to proteolysis. These observations
prompted us to explore the contribution of two arginine residues
in AKAP79 as determinants for PKC binding. Evidence that the
modi®ed AKAP79(31±52) (R39,40A) peptide was neither able to
block AKAP79±PKC binding nor inhibit kinase activity sup-
ported the notion that these basic residues within the cor-
responding region on the anchoring protein interact with PKC.
However, additional binding determinants are present within
this region, as mutation of arginines 39 and 40 in the full-length
AKAP79 protein produces less-pronounced eﬀects on PKC
inhibition and the mutated protein retained some ability to bind
PKC. It is likely that any additional binding determinants must
reside within the ®rst 75 residues of the anchoring protein, as we
have shown previously that this region alone is suﬃcient to bind
and completely inhibit PKC activity [10].
The proposed function for AKAP79 in neurons is to provide
a scaﬀold for PKA, PKC and calcineurin at postsynaptic sites
[10]. Targeting of such a multi-enzyme signalling complex would
allow local control of phosphorylation events mediated by
second-messenger signals such as the generation of cAMP,
calcium and DG. Activation of PKA or PKC could facilitate
phosphorylation of synaptic substrates such as ion channels and
neurotransmitter receptors [37,38]. AKAP79 concentrates these
enzymes at their sites of action, as demonstrated by functional
studies showing that disruption of PKA anchoring with peptide
inhibitorsaltersthemodulationofionotropicglutamatereceptors
[37]. Subsequent studies have used AKAP79 or AKAP18 as
vectors that target PKA to the membrane, thereby favouring
cAMP-dependent stimulation of substrates such as the L-type
Ca#+ channel [19,39]. Whereas the functional consequences of
PKC interaction with AKAP79 are yet to be determined, it is
interesting to note that our immunochemical data imply that
certain PKC isoforms appear to be most prevalent in the cell
bodies (Figure 6). Since PKC phosphorylation augments the ion
¯ow through N-methyl-d-aspartate (NMDA) and a-amino-3-
hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA)}kainate
receptors, which are concentrated in soma, it is tempting to
speculate that PKC anchoring provides a mechanism for facili-
tating phosphorylation at these sites [40,41]. In addition, the
dendritic location of PKCe, and to a lesser extent PKCi,i s
consistent with a proportion of these PKC isoforms being
anchored at postsynaptic sites (Figures 6E and 6H). Another
proposed function for PKC interaction with AKAP79 is phos-
phorylationoftheanchoringproteinitself.AKAP79isasubstrate
forPKCinio,andphosphorylationbyPKCregulatestargeting
of the anchoring protein to phospholipid membranes [11]. Thus
it is plausible that AKAP79 binds and inhibits PKC in order to
maintainapoolofkinaseattheoptimumsiteforphosphorylation
of the anchoring protein in response to the generation of second
messengers. This would involve the concerted and ordered action
of two signals: Ca#+±calmodulin, which releases the inhibited
kinase from contact with the anchoring protein [14], and the
PKC activator DG. Future studies are planned to assess the
contribution of AKAP79 in the functional coupling of PKC with
selected synaptic substrates.
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